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Heterologous expression and patch-clamp recording of P2X receptors in HEK293 
cells 
Lin-Hua Jiang and Sébastien Roger  
 
Running head: P2X electrophysiology in HEK293 cells 
Summary 
P2X receptors (P2XRs) are ligand-gated ion channels gated by extracellular adenosine 5’-
triphosphate (ATP) and play a critical role in mediating ATP-induced purinergic signaling 
in physiological and pathological processes. Heterologous expression of P2XR in human 
embryonic kidney 293 (HEK293) cells and measurement of P2XR-mediated currents using 
patch-clamp recording technique have been widely used to study the biophysical and 
pharmacological properties of these receptors. Combination of electrophysiology with site-
directed mutagenesis and structural information has shed light on the molecular basis for 
receptor activation and mechanisms of actions by receptor antagonists and modulators. It 
is anticipated that such methodologies will continue helping us to provide more 
mechanistic understanding of P2XRs and to test novel receptor antagonists and allosteric 
modulators for therapeutical purposes. In this chapter, we describe protocols of transiently 
or stably expressing the P2XR in HEK293 cells and measuring P2XR-mediated currents 
by using whole-cell recording. 
 







P2X receptors (P2XRs) for extracellular ATP comprise the ionotropic P2 purinergic 
receptor family. There are seven different subunits, P2X1 to P2X7, which can assemble in 
homo-/hetero-trimeric ligand-gated ion channels gated by ATP as being the physiological 
agonist (1).  P2XRs show wide expression in mammalian cells, both excitable and non-
excitable cells, and have an important role in mediating ATP-induced purinergic signaling 
in a diversity of physiological processes ranging from neuromodulation (2), immune 
response (3) to regulation of stem cell functions (4, 5).  Compelling evidence from both 
preclinical and clinical studies supports critical engagement of P2XRs in the pathogenesis 
of numerous diseases, including chronic pain (6), neurodegenerative diseases (7), mood 
disorders (8), inflammatory diseases (9), metabolic disorders (10) and cancers (11, 12). 
 Since its invention (13), the patch-clamp recording technique has been the golden 
experimental tool in the study of ion channels.  Studies using this technique of the P2XRs 
recombinant in heterologous expression cell systems have revealed distinctive biophysical 
and pharmacological properties of these receptors, which has been useful in elucidating 
their physiological and pathological roles (1).  Human embryonic kidney (HEK) 293 cells 
express no endogenous P2XR and, in addition, THEY are readily transfected with plasmids 
with good transfection efficiency, and robust in protein expression, membrane trafficking 
and post-translational modifications. The membrane of HEK293 cells is also amenable to 
formation of seal with patch-clamp electrodes. Therefore, HEK293 cells represent a widely 
used heterologous mammalian cell expression system to express the mammalian P2XRs. 
Electrophysiological studies of the P2XRs expressed in HEK293 cells, in combination with 
site-directed mutagenesis and more recently with structural information, have shed light 
on the ion-permeating pore (14), ATP binding (15-16) and conformational changes 
accompanying channel gating (17-22) as well as residues coordinating the actions of 
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antagonists and modulators (23-26).  As have been nicely summarized in recent reviews 
(27-30), electrophysiological studies using HEK293 cells and other heterologous 
expression cell systems, such as Xenopus oocytes, have provided substantial insights into 
the molecular basis that determine ATP-induced activation of the P2XRs and actions of 
P2XR antagonists and allosteric modulators. In addition, measurements of agonist-induced 
currents in HEK293 cells expressing P2XR carrying disease-associated mutations have 
been helpful in informing the mutational effects on receptor functions and thereby 
furthering our understanding of the disease mechanisms (31-33).  Electrophysiology using 
HEK293 cells as a mammalian cell expression system will continue to be a very useful 
tool to develop a better understanding of the P2XRs, particularly to test novel receptor 
antagonists and allosteric modulators for therapeutical purposes (8).   
 In this chapter, we describe protocols of using HEK293 cells to transiently and 







2.1 Cells and reagents 
1.  HEK293 cells (American Type Cell Collection). 
2. Culture medium: Dulbecco’s modified Eagles medium (DMEM)/F-12, with penicillin 
and streptomycin and 10 % foetal bovine serum (FBS). 
3. Dulbecco’s Ca2+-/Mg2+-free phosphate buffer saline (D-PBS) 
4. 0.05% trypsin-EDTA solution 
5. 400 µg/ml G418 in culture medium 
6. Opti-MEM I serum free medium (Invitrogen), or similar. 
7. Lipofectamine 2000 transfection reagent (Invitrogen), or similar. 
8.  Plasmids encoding wild-type (WT) and mutant P2XRs, generated in-house, most often 
using pcDNA3.1 vector (Invitrogen) or similar. 
 
2.2 Equipment 
1. Bench-top pH metre. 
2. Advanced Instruments Osmo1, single sample micro-osmometer. 
3. Sterile cell culture plastics: T25 vented flasks, 6-well and 96-well plates; 35-mm petri-
dishes; 5-mL, 10-mL and 25-mL plastic pipettes; 15-mL conical centrifuge tubes; 1.5-
mL microcentrifuge tubes.   
4.  2-, 10-, 20-, 200- and 1000-µL pipettes and tips. 
3. Bench top swing-out centrifuge. 
4. Haemocytometer. 
5. 13-mm glass coverslips. 
6. CO2 tissue/cell incubator. 
7. 50-mL and 10-mL syringes. 
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8. 0.22-µm-pore diameter filters.  
9. Borosilicate glass capillaries with 1.5-mm outer diameter and 1.12-mm inner diameter 
10. AgCl-coated Ag pellet reference electrode. 
11.  PP-830 glass micropipette puller (see Note 1). 
12. PC computer with 24-inch thin film transistor monitor. 
13. Axopatch 200B patch-clamp amplifier, and 1332A Digidata (Molecular Devices) (see 
Note 2). 
14. Data acquisition and analysis software: pClamp (Clampex and Clampfit; Molecular 
Devices), and Origin (OriginLab). 
15. Inverted microscope (we use Axiovert-200 from Zeiss) (see Note 3). 
16. MP-85 manual micro-manipulator (see Note 4). 
17. RSC-160 rapid solution changer (see Note 5). 
 
2.3. Recording Solutions 
Prepare recording solutions with deionized water, adjust to pH 7.3, and measure the 
osmolarity.  Store extracellular solutions at 4°C and warm to room temperature before use. 
Filter intracellular recording solution using a 50-mL syringe with a 0.22-µm-pore diameter 
filter attached and aliquot in 1-ml volume and kept at -20°C. Frost one aliquot of 
intracellular solution and thawed to room temperature before use.  
 
1. Standard extracellular recording solution: 147 mM NaCl, 2 mM KCl, 1 mM MgCl2, 2 
mM CaCl2, 13 mM D-glucose, 10 mM HEPES; pH 7.3 with NaOH; ~300 mOsm (see 
Note 15). 
2. Standard intracellular solution: 145 mM NaCl, 10 mM EGTA and 10 mM HEPES; pH 
7.3 with NaOH; ~290 mOsm (see Note 16). 
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3.  100 mM ATP and its analogues (e.g., BzATP) in water as stock solutions. Adjust ATP 
stock solution to pH 7.3 with NaON if used in mM to elicit P2X7R activation.  Aliquot 
ATP and BzATP stock solutions in small volumes, and store at -20°C. Prepare working 
solutions with desired concentrations by diluting the stock solution in extracellular 






Carry out the following procedures for cell culture, transfection and cell plating in a tissue 
culture fume hood at room temperature. Maintain HEK293 cells in culture medium (see 
Note 6) in a tissue culture incubator at 37°C and 5% CO2 under humidified conditions. 
Passage HEK293 cells or P2XR-expressing stable cells every 3-4 days or when cell 
confluency reaches ~80%. Warm all culture media to room temperature (20-22°C) before 
use. 
 
3.1 Cell Passage 
1. Remove media and rinse cells with 1 ml D-PBS. Add 1-2 ml trypsin-EDTA, and 
incubate cells at 37°C for 1-2 min (see Note 7). 
2. Once cells are detached, add 1-2 ml fresh culture medium, and transfer the cell 
suspension in a 15-ml conical centrifuge tube.  
3. Collect cells by centrifugation using a bench-top centrifuge at 1000 rpm for 5 min.  
4. Discard the supernatant, re-suspend the cell pellet gently and thoroughly in 2 ml fresh 
culture medium (see Note 8). Transfer 10-20% of cells (0.2-0.4 ml) to a new T25 flask, 
depending on the confluency of starting cell cultures, frequency of using cells and cell 
proliferation. 
 
3.2 Transient transfection 
1. For each transfection, seed ~106 cells for one well in a 6-well plate or a 35-mm petri-
dish and incubate cells overnight or until reaching 70-80% confluency. 
2. For each transfection, dilute 1 µg plasmid encoding P2XR (and 0.1 µg plasmid encoding 
enhanced green florescence protein (eGFP) for transient expression of P2XR; see Note 
9) in 100 µl Opti-MEM medium in one 1.5-ml microcentrifuge tube, and 3 µl 
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Lipofectamine 2000 into 100 µl Opti-MEM medium in a second tube. Incubate them 
for 5 min at room temperature. 
3. Combine the contents into one single tube, and incubate further 20 min.      
4. Add 800 µl fresh culture medium into the tube, and mix the content. 
5. Remove media from cell-containing well or petri-dish, and replace with the transfection 
medium (see Note 10).  
6. Return cells to the CO2 incubator, and incubate for 24-48 hr before use for patch-clamp 
recording or 48 hr for generating stable cell lines (see Note 11). 
 
3.3 Generation of stable cell lines expressing P2XR 
1. Following the steps described above in section 3.2, replace the transfection medium with 
1 ml fresh culture media containing G418 antibiotic used as the selecting agent when 
using expression vectors such as pcDNA3.1 bearing the G418 resistance gene.  
2. Culture the cells for 1-2 weeks, with replacing G418 every 2-3 days. 
3. Treat the cells with 1 ml trypsin-ETDA, plate individual islands of cells in separate wells 
in 96-well plates, and incubate the cells until confluent in the presence of G418 (see 
Note 12). 
4. Detach cells in each well with 100 µl trypsin-ETDA, transfer cells to T25 flasks, and 
grow cells in 5 ml fresh culture medium until confluent.  
5. Validate stable P2XR-expressing cells by plating cells on coverslips and measuring 
agonist-induced currents using patch-clamp recording described below (see Note 13). 
 
3.4 Cell Plating for Electrophysiological Recordings 
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1. To prepare cells for recording, remove transfection medium (for transient expression) 
or culture media, wash with D-PBS, and detach cells using trypsin-EDTA as described 
above.  
2. Place 13-mm glass coverslips (up to 4) per well in a 6-well plate or per 35-mm petri-
dish, and add 1 ml fresh culture medium in one well or petri-dish. 
2. Count cell number using a haemocytometer. Transfer 40,000 cells per well or petri-dish, 
and incubate cells for 12-24 hr before use (see Note 14). 
 
3.5 Whole-Cell Recordings 
1. Switch on the patch-clamp rig, and open Clampex for recording and RSC software that 
controls solution changes. 
2. Connect the recording chamber to solution reservoir provided by a 50-mL syringe, add 
extracellular recording solution into the syringe, and adjust solution flow at a rate of 1-
2 ml min-1. 
3. Connect the recording chamber to RSC solution tubes provided by 10-mL syringes.  Add 
agonists, antagonists, or other agents into syringes, and register them in the RSC control 
system. 
4. Check AgCl-pellet reference electrode in contact with extracellular recording solution 
and connection to the ground via the headstage of the amplifier. 
5. Prepare recording pipettes from glass capillaries using PP-830 puller. Back-fill the 
pipette with intracellular recording solution, and mount it onto the holder of the 
headstage that is connected to the amplifier via AgCl-coated silver wire (see Note 17).   
6. Lower the pipette into the extracellular solution in the recording chamber, and apply a 5 
mV test pulse to determine the resistance of the pipette, which should be in the range of 
3-5 MΩ.  
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7. Identify single cells under the microscope (see Note 18).  
8. Adjust the basal current level to zero. Manoeuvre the pipette using a micro-manipulator 
under the microscope to bring its tip into contact with cell surface, which is indicated 
with slightly increased resistance of the pipette.  
9. Apply suction to the cell membrane, through a syringe connected via a tube to the 
recording pipette, to form a gigaohm seal (in cell-attached configuration). Compensate 
the transient capacitive currents (refer to the amplifier’s manuscript for details). 
10. Apply additional suction to break-through the cell membrane to achieve whole-cell 
configuration, which is indicated by appearance of relatively slow capacitive currents 
(see Note 19). Compensate the capacitive currents. Set the membrane potential to -60 
mV or desired holding potential (see Note 20). 
11. Compensate the capacitive current by ~60-70% (see Note 21).  
12. Start recording agonist-induced P2XR-mediated currents. Apply agonists for 2 to 10 s 
through RSC at an interval of 2-4 min, depending on the activation and desensitization 
properties of the P2XR under investigation, which requires optimization 
experimentally. The following are some commonly used protocols in the study of the 
P2XRs:  
13. To determine the potency or EC50 value of an agonist by constructing the concentration-
activation relationship curve, apply agonist at 2-4 min intervals from low to high 
concentrations (see an example in Fig. 1).    
14. To determine the potency or IC50 value of an antagonist at P2XR by constructing the 
concentration-inhibition relationship curve, chose the concentration of agonist to elicit 
measureable currents (e.g., EC50 or EC90-100), apply agonist at 2-4 min intervals to 
establish stable current response, and treat the patched cell with antagonist between 
agonist applications at increasing concentrations (see an example in Fig. 2).  For the 
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antagonists with fast dissociation kinetics, co-apply antagonist with agonist as well as 
treatment with antagonist between agonist applications (see example in Fig. 3).  
15. To examine the effect of exposure to reagent, for example, dithiothreitol (DTT) used 
in cysteine substitution studies, on P2XR-mediated currents.  Apply agonist at a chosen 
concentration at 2-4 min to establish the stable current response before exposing the 






1. PP-830 is discontinued and replaced by PC-100. Other models of micropipette pullers 
from different vendors can be used.  
2. Molecular Devices provides Axopatch 200B amplifier, which offers low-noise 
recordings, particularly suitable for single-channel recording, and MultiClamp 700B 
amplifier (https://www.moleculardevices.com/products/axon-patch-clamp-
system/amplifiers/axon-instruments-patch-clamp-amplifiers). Harvard Bioscience 
provides HEKA EPC 10 USA amplifier (https://www.heka.com/products/ 
products_main.html#physiol_epc10single).  These are the most common models. 
3. Several manufactures provide inverted microscopes that are suitable for building a 
manual patch-clamp rig. A fluorescence system incorporated into the microscope is 
required to identify eGFP-positive cells, if cells are co-transfected with plasmids for 
P2XR and eGFP.  
4. There are many choices of manual and automatic micromanipulators. 
5. A computer-controlled rapid solution changing system is highly desired for application 
of agonists for a few seconds to P2XR to avoid receptor desensitization. Several 
manufacturers provide fast solution change systems.  
6. Supplementing the culture medium with antibiotics is not essential, but it is 
recommended to add 50 units/mL penicillin and 50 µg/mL streptomycin to prevent 
contamination, if required.  
7. Avoid prolonged incubation with trypsin-EDTA, particularly when plating cells for 
recording. Apply gentle taping of the flask, plate or petri-dish from side or bottom can 
help to dislodge loosely-attached cells. 
8. Use a 1000-µl pipette to pipette up and down 10-20 times and, if required, then a 200-
µL pipette to pipette up and down 10-20 times to break down cell clumps to single cells.  
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9. The efficiency of transfection has been improved using commercially available reagents 
but falls far away from 100%. Therefore, including 0.1 µg plasmid encoding eGFP 
during transfection is highly recommended, if transfected cells are used for recording 
and the microscope in the patch-clamp rig has a fluorescence system.  To select eGFP-
positive cells post-transfection for recording.  
10. The protocol in detail using Lipofectamine2000 reagent to transiently transfect the cells 
is available at: https://www.ecu.edu/cs-dhs/biochemistry/upload/Transfection-
Protocol.pdf). Several other transfection reagents or kits are also suitable for transient 
expression. 
11. Optional: if 48 hr incubation time is preferred, replace transfection medium with culture 
medium 24 hr post-transfection, and incubate cells further 24 hr before use. 
12.  Repeat this sub-cloning step, if necessary. 
13. Other methods can be used to validate the stable cell lines, such as measurement of 
agonist-induced calcium responses, or through molecular biology and biochemical 
techniques (e.g., RT-PCR, western blotting).  
14. Cells can be used for patch-clamp recording after shorter incubation times, if cells 
adhere to coverslip faster or earlier. In addition, plate cells at lower cell density if cells 
are used 36-48 hr post-transfection. 
15. P2X7Rs are inhibited by extracellular Ca2+ and Mg2+. Experiments recording P2X7R-
mediated currents often use extracellular low divalent cation solution: 147 mM NaCl, 2 
mM KCl, 0.3 mM CaCl2, 23 mM D-glucose, 10 mM HEPES, pH 7.3 with NaOH; ~300 
mOsm. Please note that it is possible but difficult to form gigaohm seal in low divalent 
cation solution. It is recommended to establish the gigaohm seal or whole-cell 




16. For not fully understood reasons, fluoride ions in the intracellular solution can improve 
seal formation and stabilise the cell membrane, favouring longer and more stable 
recordings. Replace NaCl in the intracellular solution in part or whole with NaF, if 
required.  
17. Poor chloride coating of the silver wire can result in a drift of the basal or zero current 
level over the time. Coat the silver wire regularly in bleach for 30-60 min, rinse with 
water, and dry before use.  
18. As mentioned above, if HEK293 cells are transiently co-transfected with eGFP and 
P2XR, a fluorescence microscope is required to identify eGFP-positive cells. 
19. If it is difficult to establish the whole-cell configuration following seal formation, use 
the “zap” button on the front panel of the amplifier to rupture the cell membrane. 
However, this practice is not recommended for routine use, as zapping often reduces or 
lose the sealing. 
20. Holding the cell membrane at a negative potential can help stabilize or improve the 
sealing. 
21. Determine the series resistance and cell capacitance. The cell capacitance can be used 
to derive the current density, which can mitigate the effect of the cell size on the current 
amplitude (see an example in Fig. 1). Check the series resistance during the recording 
and use data with a series resistance of no more than 10 MW. 
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Figure 1. Comparison of the sensitivity of rhesus macaque (rm) and human P2X7Rs 
to ATP and BzATP. (a) Left, representative currents evoked by different 
concentrations of ATP or BzATP in HEK293 cells expressing rmP2X7R. Right, agonist 
concentration-current curves. Each data point represents mean from 8-11 cells for ATP 
and 4-6 cells for BzATP. (b-c) Comparison of agonist concentration-current 
relationship curves between rmP2X7R and hP2X7R. The data for rmP2X7R are from 
panel (a). Each data point represents mean from 12 cells for ATP (b) and 5 cells for 
BzATP (c) for hP2X7R. The smooth curves show the fit of the mean data to the Hill 
equation. Take from (34). 
 
Figure 2. Inhibition of hP2X7R by a novel antagonist. (a) Representative currents from 
a HEK293 cell expressing hP2X7R before (CTL) and after treatment with compound 
C23 at different concentrations. Currents were elicited in extracellular low divalent 
cation solution by 4-s application of 300 µM BzATP at an interval of 2-4 min. Current 
inhibition was reversed upon washing. (b) Antagonist concentration-current inhibition 
relationship curves. Each data point represents mean from 4 cells. The smooth line 
shows the fit of the mean data to the Hill equation. Modified from (35). 
 
Figure 3. Inhibition of rhesus macaque and human P2X7Rs by A!438079. (a) 
Representative ATP-induced currents in HEK293 cells expressing rmP2X7R or 
hP2X7R in the absence (control) or presence of different concentrations of A!438079. 
Currents were evoked by 4-s application of 3 mM ATP at rmP2X7R and 1 mM at 
hP2X7R every 4 min. Cells were exposed to A!438079 between and during ATP 
applications. (b) Comparison of antagonist concentration–current inhibition curves 
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between rmP2X7R and hP2X7R. The smooth lines show the fit of the mean data to the 
Hill equation. Modified from (34). 
 
Figure 4. DTT-induced reversible increase in BzATP-induced currents in HEK293 
cells expressing hP2X7R carrying D48C/I331C double cysteine mutations. (a) 
Representative currents induced by 4-s application of 300 µM BzATP every 2 min 
before, during and after exposure to 10 mM DTT in cells expressing WT, D48C, I331C 
or D48C/I331C mutant hP2X7R. (b) Mean BzATP-induced currents at the end of 10-
min exposure to DTT (grey) as % of control currents (black). DTT reversibly increased 
BzATP-induced currents in cells expressing D48C/I331C mutant hP2X7R, but WT, 
D48C or I331C mutant hP2X7R. Such results are interpreted to indicate that D48 and 
I331 residues, located in the outer ends of the first and second transmembrane segments, 
respectively, are in close vicinity in close state, and these parts undergo substantial 
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